PCRX vs MRK: Which Stock is Better?

Side-by-side comparison of Pacira BioSciences, Inc. and Merck & Company Inc in 2026

Comparison Updated:

PCRX

Pacira BioSciences, Inc.

MRK

Merck & Company Inc

$126.78

Key Metrics Comparison

MetricPCRXMRKWinner
Market Cap$890.84M$285.12BMRK
P/E Ratio174.1532.52MRK
EPS (TTM)$N/A$N/ATie
Revenue Growth0.0%0.0%Tie
Gross Margin0.0%0.0%Tie

Analyze PCRX

Full quant analysis

Analyze MRK

Full quant analysis

Analyze Each Stock

Frequently Asked Questions

Is PCRX or MRK a better investment?

Comparing PCRX and MRK: Pacira BioSciences, Inc. has a market cap of $890.84M while Merck & Company Inc has $285.12B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.

What is the difference between PCRX and MRK?

PCRX (Pacira BioSciences, Inc.) and MRK (Merck & Company Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.

Which stock has better value: PCRX or MRK?

Based on P/E ratios, MRK trades at a lower multiple (32.5x vs 174.2x).

Which is growing faster: PCRX or MRK?

Both PCRX and MRK show similar growth rates. Check our detailed analysis for quarterly trends.

Which company is more profitable: PCRX or MRK?

Both companies show comparable profitability metrics. View the full comparison above for detailed analysis.

Which is the larger company: PCRX or MRK?

Merck & Company Inc (MRK) is larger with a market cap of $285.12B compared to $890.84M for PCRX.

Should I buy PCRX or MRK in 2026?

Both PCRX and MRK have investment merit. PCRX trades at $N/A while MRK trades at $126.78. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.

What are the key differences between PCRX and MRK stock?

Key differences: Market Cap ($890.84M vs $285.12B), P/E Ratio (174.2x vs 32.5x), Revenue Growth (0.0% vs 0.0%), Gross Margin (0.0% vs 0.0%).

Should I buy PCRX or MRK in 2026?

The choice between PCRX and MRK depends on your investment goals. MRK shows higher revenue growth (0.0%). MRK has better margins (0.0%). Consider your risk tolerance and time horizon.

What is the market cap comparison between PCRX and MRK?

PCRX (Pacira BioSciences, Inc.) has a market cap of $890.84M, while MRK (Merck & Company Inc) has a market cap of $285.12B. MRK is the larger company by market value.

Popular Stock Comparisons